COVID-19 Response

The Oxford BioDynamics facility remains operational and is continuing to provide biomarker support for clinical trials worldwide during this challenging period.

EpiSwitch™ selected for prognostic and predictive profiling of COVID-19 patients. 

Read more…

Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch™


Chromosome conformation capture to discover candidate epigenetic markers of Multiple Sclerosis disease severity.

Sangurdekar, D., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146797/tatiana.plavina.chromosome.conformation.capture.to.discover.candidate.html?f=m3

Epigenetic profile of chromosome conformation signatures underlying multiple sclerosis and its severity.

Joesph, JP., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146441/joyce.joseph.epigenetic.profile.of.chromosome.conformation.signatures.html?f=m3

Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment and Trials.

Jeznach, M.
International Pharmaceutical Industry
https://issuu.com/mark123/docs/ipi_march2016_web/45

Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients.

Carini, C., et. al.,
Annual Meeting of the American College of Rheumatology
http://acrabstracts.org/abstract/epigenetic-chromosome-conformations-predict-mtx-responsiveness-in-early-rheumatoid-arthritis-patients/

Development of Epigenetic Profiling of ALS Patients with Chromosome Conformation Biomarkers Offers Novel Signatures for Non-invasive Diagnostic and Prognostic Stratifications.

Hunter, E., et. al.,
14th Annual Northeast Amyotrophic Lateral Sclerosis Consortium
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSNEALS2015.pdf

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.

Jakub, JW., et. al.,
Melanoma Research
https://www.ncbi.nlm.nih.gov/pubmed/26225582

Chromatin barcodes as biomarkers for melanoma.

Bastonini, E., et. al.,
Pigment Cell Melanoma Research
https://www.ncbi.nlm.nih.gov/pubmed/24807349

A blood-based epigenetic test for early detection of hepatocellular carcinoma (HCC).

Lim, EH., et. al.,
J Clinical Oncology
http://meetinglibrary.asco.org/content/133682-144

Chromatin signatures of DLBCL subtypes.

Field, et. al.,
Cancer Research
http://cancerres.aacrjournals.org/content/74/19_Supplement/462

Current Advances in Epigenetics.

Hunter, et., al.,
Clinical and Statistical Consideration in Personalized Medicine
http://www.oxfordbiodynamics.com/2014/03/27/current-advances-in-epigenetics/